Galectin Therapeutics Reports Q4 Earnings: FY GAAP EPS of -$0.48, Beats by $0.01

martes, 31 de marzo de 2026, 8:38 am ET1 min de lectura
GALT--

Galectin Therapeutics reported FY GAAP EPS of -$0.48, beating the consensus by $0.01. The company had $17.7 million of unrestricted cash and cash equivalents as of December 31, 2025, and $10 million available under a line of credit.

Galectin Therapeutics Reports Q4 Earnings: FY GAAP EPS of -$0.48, Beats by $0.01

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios